PACB Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $39 million, slightly down from $39.8 million in Q2 2025.

Instrument Revenue: $12.8 million, a 9% decrease from $14.2 million in Q2 2025.

Consumables Revenue: $20.1 million, up 6% year-over-year from $18.9 million.

Non-GAAP Gross Profit: $13.9 million with a gross margin of 36%, down from 38% in Q2 2025.

Non-GAAP Net Loss: $41.9 million ($0.14 per share), compared to a loss of $40 million ($0.13 per share) in the prior year.

Cash Position: $236.9 million at quarter-end, down from $279.5 million at the end of 2025.

2Strategic Updates and Business Highlights

Leadership Transition: Mark Van Oene has succeeded Christian Henry as CEO, with Henry remaining on the Board.

SPRQ-Nx Chemistry Launch: Full global rollout has begun, with strong customer interest; over a third of the installed base adopted the new software.

Clinical Market Growth: Consumables shipments to clinical customers grew 67% year-over-year, representing a mid-teens percentage of total consumable shipments.

Revio and Vega Systems: Sold 20 Revio systems (up from 15) and 26 Vega systems (down from 38). Cumulative shipments stand at 366 Revio and 200 Vega systems.

Scientific Validation: Recent publications support the effectiveness of HiFi long-read sequencing in clinical diagnostics, enhancing the company's credibility.

3Forward Guidance and Outlook

Revenue Guidance: Revised down to $155 million to $165 million for 2026, reflecting expected consumables growth but tempered by ongoing funding uncertainties.

Gross Margin Outlook: Expected to be in the range of 35% to 37% for 2026, impacted by temporary manufacturing transition costs and elevated compute costs.

Cash Burn Expectations: Anticipated to decrease significantly in 2027, with cash flow breakeven now expected in 2028.

4Bad News, Challenges, or Points of Concern

Funding Constraints: Ongoing uncertainty in academic and government funding, particularly in the Americas, continues to affect capital purchases.

Vega Sales Decline: Vega system sales decreased due to funding issues, although ASP has returned to normalized levels.

Gross Margin Pressures: Declining gross margins due to compute cost inflation and transition costs associated with in-house manufacturing of Vega systems.

Market Dynamics: The transition to SPRQ-Nx may lead to short-term challenges as customers validate workflows and deplete existing inventories.

5Notable Q&A Insights

Customer Adoption: Majority of Revio placements are to clinical accounts, indicating strong momentum in the clinical market.

SPRQ-Nx Impact: Expected to drive consumables growth in the second half of the year as customers optimize workflows.

Restructuring Focus: The recent organizational changes aim to align marketing with clinical sales, enhancing focus on growth opportunities in the clinical sector.

Biopharma Interest: There is increasing demand for comprehensive genomic data, with multiomics becoming a focal point for biopharma partners. This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A, providing a balanced view of PacBio's current performance and outlook.